Effect of Pentoxifylline on Anemia in Hemodialysis Patients
Launched by ALEXANDRIA UNIVERSITY · Jan 23, 2023
Trial Information
Current as of June 22, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Both sexes of HD patients
- • Age \>20 years
- • Patients who have adequate hemodialysis for at least 6 months
- • Hb level ≤ 10.5 g/dl
- Exclusion Criteria:
- • Recently dialyzed patients (less than 6 months)
- • Patients with known sensitivity to theophylline or other xanthine derivatives
- • Severe iron deficiency with serum ferritin \< 100 µg/dL and/or TSAT \< 20%
- • Planning for pregnancy, pregnancy, or lactation
- • Patients with severe liver disease or other organ failure
- • Previous renal transplantation, noncompliance with medication or HD prescription, or inability to oral drug administration
- • Malignancy within last 3 months
About Alexandria University
Alexandria University, a leading academic institution in Egypt, is dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise to conduct rigorous studies that address pressing health challenges. By fostering partnerships with healthcare professionals, industry leaders, and regulatory bodies, Alexandria University aims to contribute to the global body of medical knowledge and enhance the quality of patient care through evidence-based findings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mansoura, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials